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Available online xxxxBackground: Psychosis is a condition inﬂuenced by an interaction of environmental and genetic factors. Gene ex-
pression studies can capture these interactions; however, studies are usually performed in patients who are in
remission. This study uses blood ofﬁrst episode psychosis patients, in order to characterise deregulatedpathways
associated with psychosis symptom dimensions.
Methods: Peripheral blood from 149 healthy controls and 131 ﬁrst episode psychosis patients was proﬁled using
Illumina HT-12 microarrays. A case/control differential expression analysis was performed, followed by correla-
tion of gene expression with positive and negative syndrome scale (PANSS) scores. Enrichment analyses were
performed on the associated gene lists. We test for pathway differences between ﬁrst episode psychosis patients
who qualify for a Schizophrenia diagnosis against those who do not.
Results:A total of 978 geneswere differentially expressed and enriched for pathways associated to immune func-
tion and themitochondria. Using PANSS scoreswe found that positive symptomseveritywas correlatedwith im-
mune function, while negative symptoms correlated with mitochondrial pathways.
Conclusions: Our results identiﬁed gene expression changes correlated with symptom severity and showed that
key pathways are modulated by positive and negative symptom dimensions.
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Immune system1. Introduction
Psychosis is a debilitating disorder characterised by hallucinations,
delusions and thought disorder, that affects approximately 4 in 1000 in-
dividuals in the UK each year (Kirkbride et al., 2012). It is a core feature
of severe mental illnesses, such as schizophrenia and bipolar disorder,
where treatment commonly involves the long-term use of anti-
psychotic medication. However, the response to antipsychotics varies
between patients, and is associated with the burden of signiﬁcant
side-effects. In order to ﬁnd a tolerable treatment, it is often necessary
for newly diagnosed patients to trial multiple antipsychotics. Develop-
ing a better understanding of psychosis subtypes could therefore beneﬁte, M. Di Forti, et al., Differenti
016/j.schres.2019.05.011patients by identifying biomarkers that correlate with medication
tolerance.
Schizophrenia and Bipolar disorder are both thought to be highly
heritable, and recent genomewide association studies suggest that hun-
dreds of common genetic variants contribute to disease risk (Ripke
et al., 2014). The most prominent results from schizophrenia genetic
studies have been associations to the major histocompatibility complex
(MHC) locus, which implicates the immune system. Transcriptomic
studies in blood have also consistently identiﬁed disruptions in immune
pathways both in schizophrenia (Gardiner et al., 2013) and in bipolar
disorder (Jansen et al., 2016). Recent meta analyses of transcriptome
data have further strengthened these ﬁndings and found common and
abnormal cytokine patterns in patients with chronic depression, bipolar
disorder or schizophrenia (Goldsmith et al., 2016).
While psychosis is obviously closely linked to the brain, expression
changes, are not necessarily linked to brain tissue. Peripheral geneal gene expression analysis in blood of ﬁrst episode psychosis patients,
2 D.J. Leirer et al. / Schizophrenia Research xxx (xxxx) xxxexpression changes can plausibly be detected in blood, especially in the
case of the immune system. In a meta-analysis of Schizophrenia tran-
scriptomics (Hess et al., 2016) that pooled 18 previously published
blood and brain-based studies the authors found signiﬁcant overlap in
dysregulated pathways between both tissues, including the upregula-
tion of innate immune pathways. Blood based transcriptomic studies
have the additional advantage of capturing complex gene environment
interactions, at key points during disease progression. This includes ﬁrst
episode psychosis which is of special interest since patients will get
treatment for the ﬁrst time, following an acute episode of symptoms.
However, there are few studies that focus speciﬁcally on the tran-
scriptome of ﬁrst episode psychosis (FEP) patients, when they ﬁrst en-
counter mental health services. One notable exception is a
Singaporean study which identiﬁed a 400 gene signature to distinguish
FEP patients and healthy controls (Lee et al., 2012), however this study
was limited to 26 patients and did not distinguish between positive and
negative symptom dimensions.
To investigate the potential relationship between psychosis speciﬁc
gene expression changes, and diagnostic/symptom dimensions, we
make use of the Genetics and Psychosis (GAP) study (Di Forti et al.,
2009). GAP contains transcriptome data derived from the whole blood
of healthy controls (HC), as well as FEP patients. While these patients
did receive anti-psychotic medication where necessary, they were re-
cruitedwithin oneweek of admission to hospital, and exposure tomed-
ication was therefore limited compared to chronic psychosis sufferers'
who may have taken medication continuously for many years.
We report the results of a case-control differential gene expression
(DGE) and pathways analysis using the GAP transcriptome data. This
is followed by investigating the correlation between psychosis path-
ways and symptom dimensions. Finally, we compare how the disrup-
tion of pathways differs in FEP patients who qualify for a
Schizophrenia diagnosis and those who do not.
2. Methods and materials
2.1. Ethics
The Genetics and Psychotic Disorders (GAP) Study received ethical
approval from the South London and Maudsley NHS Foundation Trust
(SLaM), as well as from the Institute of Psychiatry, Psychology and Neu-
roscience Local Research Ethics Committee, IOPPN/SLaM research ethics
approval number: 135/05. Informedwritten consentwas obtained from
all participants in the study by the GAP team.
2.2. Study design and participants
As part of the GAP study (Di Forti et al., 2009, 2015), Patients aged 18
to 65 years who presented with ﬁrst-episode psychosis at the inpatient
units of SLaMwere approached for recruitment. Patientswere invited to
participate if theymet the ICD-10 criteria for a diagnosis of non-affective
(F20 to F29) or affective (F30 to F33) psychosis (Guest et al., 2014), val-
idated by administration of the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) (Aboraya et al., 1989), they were re-
contacted after the start of treatment.
Between May 1, 2005, and May 31, 2011, 461 patients with ﬁrst-
episode psychosis were recruited. The cohort consisted of a diverse
multi-ethnic population. Further patient information, blood samples
and genetic ancestry were acquired as described previously (Di Forti
et al., 2012). During the same period, a total of 389 control individuals
were recruited. These individuals were aged 18–65 years andwere sim-
ilar to the local population regarding gender, ethnic origin, education,
employment status and socio-economic status. Recruitment of controls
was done using Internet and newspaper advertisements and by distrib-
uting leaﬂets at train stations, shops, and job centres. Volunteers were
administered the Psychosis Screening Questionnaire (Bebbington andPlease cite this article as: D.J. Leirer, C.O. Iyegbe, M. Di Forti, et al., Differenti
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disorder or if they reported a previous diagnosis of psychotic illness.
The OPCRIT system (Rucker et al., 2011) was used to assign ICD-10
and DSM-IV diagnostic categories in a systematic way. For subset anal-
yses including diagnosis, patients who ﬁt the diagnostic criteria for
schizophrenia under either the ICD or DSM system were assigned to
the schizophrenia (Scz) group, while all other patients were assigned
to the other psychosis group (OP).
2.3. RNA processing and quality control
Whole blood samples were collected using PAXgene tubes for RNA,
from a subset of GAP participants (227 cases and 168 controls) within
the ﬁrst two weeks of recruitment. Samples were run at the NIHR
Maudsley Biomedical Research Centre for Mental Health (BRC-MH)mi-
croarray facility at the SGDP, Institute of Psychiatry, Psychology and
Neuroscience, King's College London, UK. Microarrays where run in ac-
cordance with the manufacturer's protocol using Illumina HT-12 V4
bead-chips (Illumina, USA).
All analysis was performed using R version 3.1.2. Pre-processing of
the data was performed using an in-house developed pipeline.
The pipeline takes raw gene expression data exported from
Illumina's Genomestudio, performs background correction (Xie et al.,
2009) using negative bead expression levels in order to correct for
noise. Lumi (version 2.22.1 Du et al. (2008)) was used to log base 2
transform the data followed by robust spline normalization (Du et al.,
2008). Outlying samples were iteratively identiﬁed using fundamental
network concepts and removed, following the methods described by
Oldham et al. (2012).
In order to reduce the inﬂuence of batch effectswe adjusted for tech-
nical categorical variables using multiple linear regression and ComBat
(Leek et al., 2010). Other Continuous technical artefacts were accounted
for by taking the ﬁrst principal component across housekeeping and un-
detected probes and regressing this against technical variables. Four
variables were signiﬁcantly associated with PC1, these were as follows:
“The date that Samples were thawed”, “Concentration of initial RNA”,
“Concentration of labelled cRNA” and “Date of RNA puriﬁcation”. They
were regressed against expression for each probe, and the mean ad-
justed residuals where taken forward for all further analysis. The RNA
integrity number (RIN) was include in the list of variables but was not
signiﬁcantly correlated with the ﬁrst principle component. We did not
use a RIN cut-off, to preserve sample size, as a result 24 samples had a
RIN between 8 and 5.
The expression data was further tested for hidden covariates using
surrogate variable analysis (Leek and Storey, 2007). FEP andControl sta-
tus was included in themodel to preserve the biological signal between
groups. Following this we compared recorded gender with gender de-
termined by XIST and PRKY probes and excluded samples that showed
a mismatch. Finally, we excluded all probes that could not be reliably
detected in 80% of the samples in at least one diagnostic group. We
used the R package CellMix version 1.6 (Gaujoux and Seoighe, 2013),
to test for potential signiﬁcant differences in whole blood cell popula-
tions between cases and controls and these were included in limma
models.
2.4. Differential expression analysis
Standard Differential expression analysis was performed using the R
package LIMMA (Smyth, 2004) (version 3.26.8). Prior to analysis we
accounted for potential covariates by performingmultiple linear regres-
sion on all probes with CellMix proportions, age, sex and ethnicity as in-
dependent variables. Mean adjusted residuals were used in all
subsequent analysis. Probes were declared signiﬁcantly differentially
expressed if the FDR adjusted q-value was b0.05 and the absolute log
fold change was above 0.1. Differential expression was ﬁrstly tested in
ﬁrst episode psychosis (FEP) group vs healthy controls followed by aal gene expression analysis in blood of ﬁrst episode psychosis patients,
Table 1
Demographics.
Healthy
control
(n = 149)
First Episode Psychosis
(n = 131)
Schizophrenia
(n = 68)
Other
psychosis
(n = 63)
p-value
Sex = MALE (%) 86 (57.7) 45 (66.2) 31 (49.2) 0.145
Age (mean (sd)) 29.87 (10.53) 26.59 (7.67) 30.03 (9.22) 0.047
Ethnicity (%) 0.102
Asian 10 (6.7) 6 (8.8) 6 (9.5)
Black 43 (28.9) 33 (48.5) 22 (34.9)
Other 10 (6.7) 5 (7.4) 5 (7.9)
White 86 (57.7) 24 (35.3) 30 (47.6)
PANSS scores (mean
(sd))
Positive scale 16.70 (6.88) 15.49 (6.00) 0.344
Negative scale 17.20 (6.90) 14.76 (6.08) 0.065
Anti-psychotic type (%) 0.6
Antipsychotic free 9 (13.2) 9 (14.3)
Olanzapine 22 (32.4) 24 (38.1)
Risperidone 14 (20.6) 13 (20.6)
Amisulpride 0 (0.0) 1 (1.6)
Aripiprazole 9 (13.2) 3 (4.8)
Haloperidol 2 (2.9) 4 (6.3)
Quetiapine 4 (5.9) 2 (3.2)
Sulpiride 1 (1.5) 0 (0.0)
Triﬂuoperazine 1 (1.5) 0 (0.0)
Unknown 6 (8.8) 7 (11.1)
Table of Demographics for healthy control (HC) and ﬁrst episode psychosis (FEP) groups.
FEP patients are separated by diagnosis into Schizophrenia andOther Psychosis. The study
included 280 individuals. Schizophrenia patients were found to be slightly younger than
controls and other patients. No signiﬁcant difference was found for Gender, Ethnicity,
PANSS scores or Anti-psychotic type. Pvalues were calculated using the chi-square test
for categorical variables, and t-test for continues variables.
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chosis (OP) groups with healthy controls.
2.5. Symptom severity
Illness severity was assessed by using the Positive andNegative Syn-
drome Scale (PANSS) (Kay et al., 1987), which consists of 30 questions,
each ranging from 1 (not present) to 7 (extreme). The PANSS is
subdivided into 3 subscales with the positive and negative subscales
containing 7 questions each and the general psychopathology subscale
containing 16 questions.
Correlation between patient PANSS scores and differentially
expressed probes was calculated using Pearson's r, implemented by
the rcorr function in the Hmisc r package. Probe correlations with a p-
value below 0.05 were ﬁltered out. Remaining probes were used in
gene enrichment analysis.
2.6. Gene enrichment analysis
All enrichment analysis was performed using the
UserListEnrichment function of the WGCNA package (Langfelder and
Horvath, 2008). Enrichment analysis, for the results of the LIMMA anal-
ysis, was performed by testing differentially expressed probes (q-
value≤0.05 and logFC N0.1). All probes that did not pass the q-value
threshold were included as background.
In all cases KEGG (Kanehisa et al., 2004) and GO (Ashburner et al.,
2000) databases taken from the Enrichr website were used (http://
amp.pharm.mssm.edu/Enrichr/st accessed 05. July.2016). The databases
used were KEGG 2016, GO Molecular Function 2015, GO Cellular Com-
ponent and GO Biological Process 2015. Additionally, internal lists
from the UserListEnrichment function in WGCNA were used. These
were Brain Modules (useBrainLists), Brain Region Markers
(useBrainRegionMarkers) and Blood Atlases (useBloodAtlases). Gene
lists speciﬁcally compiled for Psychosiswere included frompublications
by Purcell et al. (2014) and Pirooznia et al. (2016). Result categories that
contained b20 overlapping probes were ﬁltered out.
2.7. Anti-psychotic medication
Psychosis patients were received standard care (including anti-
psychotics where necessary) until they were stabilised, and blood sam-
ples were then obtained within the ﬁrst two weeks of recruitment. To
assess the effect of medication on gene expression, we ﬁrst identiﬁed
the antipsychotics medication that patients were taking at the time of
blood collection. We grouped FEP samples based on the three most
common antipsychotic categories which were as follows: Olanzapine
(N = 46), Risperidone (N = 27) and antipsychotic free (N = 18). We
performed differential expression analysis between the three medica-
tion groups and controls.
3. Results
3.1. Sample characteristics
Demographics data is shown in Table 1. Transcriptomic data was
available for 280 samples, 149 of these corresponded to healthy controls
(HC), and 131 to ﬁrst episode psychosis (FEP) patients. The FEP group
further consisted of 68 patients with a Schizophrenia diagnosis and 63
patients with other psychoses, according to the OPCRIT system
(Rucker et al., 2011). The other psychosis group primarily ﬁt the DSM-
IV categories of mania (n= 16), schizo-affective disorder (n= 15), de-
pressionwith psychosis (n=12) and psychosis NOS (n=10) (see Sup-
plementary Table 1). FEP with a diagnosis of Schizophrenia was on
average younger than other FEP patients and controls. FEP patients
had similar exposures to antipsychotic medication, independently
from diagnosis, with Olanzapine and Risperidone being the mostPlease cite this article as: D.J. Leirer, C.O. Iyegbe, M. Di Forti, et al., Differenti
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to PANSS assessment (Leucht et al., 2005), with those with a diagnosis
of schizophrenia presenting with slightly higher scores for positive
and negative symptoms subscales than FEP with other psychoses (see
Table 1).
3.2. Differential expression analysis
We identiﬁed 978 differentially expressed genes between FEP and
HC, 509 of these were upregulated and 469 were downregulated in
FEP. The most signiﬁcantly upregulated genes were SUMO3, CAMP,
DEFA1B, DEFA1 and DEFA3. The most signiﬁcantly downregulated
genes were HNRNPUL2, RBM14, TMEN69, SCAP and FAM110A (see
Table 2, and Supplementary Table 2).
Gene Enrichment analysis identiﬁed 116 signiﬁcant pathways. They
overlapped substantially, and fundamentally corresponded to just a
handful of distinct gene lists and pathways, including ribosomal func-
tion/transcription regulation, immune signalling, and energy metabo-
lism (see Table 3, Supplementary Table 3).
All 978 differentially expressed probes were correlated with the
PANSS subscales. For the positive and negative subscales, we identiﬁed
120 and 37 signiﬁcantly correlated probes respectively (Supplementary
Table 4). Gene enrichment analysis of probes found positive symptoms
were correlated with immune pathways (NF-κB, Ras and cytokine sig-
nalling), while negative symptoms were correlated to ribosomal path-
ways (see Table 4 and Supplementary Table 4).
3.3. Differences between schizophrenia and other psychosis
In order to explore differences in FEP subgroups we replicated anal-
yses by independently comparing the Schizophrenia (Scz) and Other
Psychosis (OP) groups with healthy controls (HC). Analysis using a Sczal gene expression analysis in blood of ﬁrst episode psychosis patients,
Table 2
Top differentially expressed probes.
Gene FEP vs HC Scz vs HC OP vs HC Chr
Top 50 Up-regulated - logFC (q-value)
CAMP 0.66 (b0.001) 0.94 (b0.001) 0.38 (0.058) 3
DEFA1B 0.97 (b0.001) 1.25 (b0.001) 0.69 (0.042) 8
DEFA3 0.95 (b0.001) 1.24 (b0.001) 0.66 (0.046) 8
DEFA1 0.87 (b0.001) 1.1 (b0.001) 0.64 (0.041) 8
C9ORF72 0.24 (b0.001) 0.3 (b0.001) 0.19 (0.041) 9
CLNS1A 0.18 (b0.001) 0.23 (b0.001) 0.13 (0.049) 11
SUMO3 0.11 (b0.001) 0.12 (b0.001) 0.1 (0.022) 21
TMEM170B 0.3 (b0.001) 0.36 (b0.001) 0.25 (0.037) 6
PSMC2 0.14 (b0.001) 0.18 (b0.001) 0.1 (0.050) 7
HBXIP 0.1 (b0.001) 0.13 (b0.001) 0.07 (0.053) 1
PARL 0.1 (b0.001) 0.12 (b0.001) 0.07 (0.048) 3
IFNGR1 0.16 (b0.001) 0.19 (b0.001) 0.12 (0.050) 6
GLRX 0.24 (b0.001) 0.29 (b0.001) 0.19 (0.042) 5
IDH1 0.14 (b0.001) 0.16 (b0.001) 0.12 (0.036) 2
TCEB1 0.14 (b0.001) 0.16 (b0.001) 0.11 (0.041) 8
CCPG1 0.17 (b0.001) 0.21 (b0.001) 0.13 (0.046) 15
LYPLAL1 0.18 (b0.001) 0.2 (b0.001) 0.16 (0.037) 1
SLC30A9 0.18 (b0.001) 0.2 (b0.001) 0.15 (0.037) 4
TMBIM4 0.08 (b0.001) 0.1 (b0.001) 0.07 (0.044) 12
FAM96A 0.25 (b0.001) 0.29 (b0.001) 0.2 (0.040) 15
FAM45A 0.13 (b0.001) 0.16 (b0.001) 0.1 (0.048) 10
GNG10 0.31 (b0.001) 0.39 (b0.001) 0.24 (0.053) 9
C14ORF100 0.15 (b0.001) 0.17 (b0.001) 0.12 (0.040) 14
COX7A2 0.22 (b0.001) 0.27 (b0.001) 0.18 (0.046) 6
TAF7 0.2 (b0.001) 0.24 (b0.001) 0.17 (0.040) 5
MAP2K1IP1 0.21 (b0.001) 0.25 (b0.001) 0.17 (0.046) 4
CRLS1 0.21 (b0.001) 0.24 (b0.001) 0.17 (0.041) 20
COX7A2L 0.19 (b0.001) 0.21 (b0.001) 0.16 (0.037) 2
ATP5C1 0.24 (b0.001) 0.29 (b0.001) 0.2 (0.045) 10
FBXL5 0.13 (b0.001) 0.15 (b0.001) 0.1 (0.049) 4
UQCRQ 0.28 (b0.001) 0.33 (b0.001) 0.23 (0.046) 5
BNIP2 0.18 (b0.001) 0.19 (b0.001) 0.16 (0.037) 15
SLC35A1 0.19 (b0.001) 0.23 (b0.001) 0.15 (0.059) 6
RPSA 0.16 (b0.001) 0.2 (b0.001) 0.12 (0.061) 3
LYST 0.14 (b0.001) 0.16 (b0.001) 0.12 (0.046) 1
WDR61 0.13 (b0.001) 0.16 (b0.001) 0.11 (0.044) 15
SRP9 0.2 (b0.001) 0.22 (b0.001) 0.18 (0.038) 1
VBP1 0.22 (b0.001) 0.25 (b0.001) 0.19 (0.041) X
PCMT1 0.14 (b0.001) 0.14 (b0.001) 0.13 (0.036) 6
TMX1 0.25 (b0.001) 0.29 (b0.001) 0.2 (0.048) 14
SLC44A1 0.18 (b0.001) 0.19 (b0.001) 0.16 (0.036) 9
PRDX3 0.13 (b0.001) 0.14 (b0.001) 0.12 (0.037) 10
COX17 0.13 (b0.001) 0.15 (b0.001) 0.11 (0.042) 3
KIAA1600 0.19 (b0.001) 0.22 (b0.001) 0.15 (0.050) 10
PIGY 0.17 (b0.001) 0.2 (b0.001) 0.15 (0.044) 4
COMMD3 0.17 (b0.001) 0.21 (b0.001) 0.14 (0.049) 10
KBTBD11 0.16 (b0.001) 0.19 (b0.001) 0.13 (0.050) 8
TMEM14B 0.16 (b0.001) 0.19 (b0.001) 0.13 (0.055) 6
VAMP7 0.15 (b0.001) 0.16 (b0.001) 0.14 (0.036) XY
LDHA 0.11 (b0.001) 0.11 (b0.001) 0.11 (0.036) 11
Top 50 Down-regulated - logFC (q-value)
RBM14 −0.13 (b0.001) −0.17 (b0.001) −0.09 (0.046) 11
HNRNPUL2 −0.19 (b0.001) −0.23 (b0.001) −0.14 (0.040) 11
GABPB2 −0.09 (b0.001) −0.11 (b0.001) −0.06 (0.053) 1
FAM110A −0.16 (b0.001) −0.19 (b0.001) −0.12 (0.046) 20
SCAP −0.14 (b0.001) −0.17 (b0.001) −0.11 (0.046) 3
PNPT1 −0.11 (b0.001) −0.14 (b0.001) −0.08 (0.050) 2
RASGRP2 −0.12 (b0.001) −0.15 (b0.001) −0.09 (0.050) 11
ZC3H5 −0.11 (b0.001) −0.13 (b0.001) −0.08 (0.057)
TMEM69 −0.11 (b0.001) −0.13 (b0.001) −0.1 (0.037) 1
CLSTN1 −0.16 (b0.001) −0.2 (b0.001) −0.12 (0.058) 1
GANAB −0.12 (b0.001) −0.15 (b0.001) −0.09 (0.054) 11
DENND4B −0.12 (b0.001) −0.14 (b0.001) −0.09 (0.046) 1
ZNF296 −0.16 (b0.001) −0.19 (b0.001) −0.13 (0.042) 19
KIAA1267 −0.1 (b0.001) −0.13 (b0.001) −0.08 (0.051) 17
CXXC1 −0.12 (b0.001) −0.14 (b0.001) −0.1 (0.046) 18
POM121C −0.13 (b0.001) −0.16 (b0.001) −0.1 (0.049) 7
RANGAP1 −0.12 (b0.001) −0.15 (b0.001) −0.1 (0.050) 22
STIP1 −0.14 (b0.001) −0.17 (b0.001) −0.1 (0.060) 11
ITPKB −0.13 (b0.001) −0.16 (b0.001) −0.1 (0.055) 1
CD97 −0.16 (b0.001) −0.2 (b0.001) −0.13 (0.053) 19
HGS −0.1 (b0.001) −0.13 (b0.001) −0.08 (0.060) 17
SUPT5H −0.14 (b0.001) −0.16 (b0.001) −0.11 (0.042) 19
UBQLN4 −0.12 (b0.001) −0.14 (b0.001) −0.1 (0.044) 1
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Table 2 (continued)
Gene FEP vs HC Scz vs HC OP vs HC Chr
SPG7 −0.11 (b0.001) −0.13 (b0.001) −0.08 (0.058) 16
RAB11FIP1 −0.14 (b0.001) −0.16 (b0.001) −0.12 (0.046) 8
TRIM28 −0.14 (b0.001) −0.16 (b0.001) −0.11 (0.053) 19
WDR23 −0.12 (b0.001) −0.13 (b0.001) −0.1 (0.041) 14
GPS1 −0.09 (b0.001) −0.1 (b0.001) −0.08 (0.046) 17
FBXO46 −0.16 (b0.001) −0.18 (b0.001) −0.15 (0.041) 19
TLN1 −0.21 (b0.001) −0.24 (b0.001) −0.18 (0.044) 9
ABCF1 −0.11 (b0.001) −0.13 (0.001) −0.09 (0.060) 6
ORC6L −0.1 (b0.001) −0.11 (0.001) −0.08 (0.046) 16
UBA1 −0.17 (b0.001) −0.2 (0.001) −0.13 (0.061) X
SRRM2 −0.11 (b0.001) −0.14 (0.001) −0.09 (0.057) 16
PDPR −0.21 (b0.001) −0.24 (0.001) −0.18 (0.047)
XRCC6 −0.13 (b0.001) −0.14 (0.001) −0.11 (0.046) 22
LBA1 −0.18 (b0.001) −0.21 (0.001) −0.16 (0.048) 3
GCN1L1 −0.12 (b0.001) −0.14 (0.001) −0.1 (0.052) 12
C21ORF58 −0.12 (b0.001) −0.14 (0.002) −0.1 (0.061) 21
EMD −0.09 (b0.001) −0.1 (0.002) −0.07 (0.059) X
ST3GAL1 −0.14 (b0.001) −0.15 (0.002) −0.13 (0.037) 8
TSSC4 −0.11 (b0.001) −0.11 (0.002) −0.1 (0.037) 11
EDC4 −0.1 (b0.001) −0.11 (0.002) −0.1 (0.037) 16
CORO7 −0.12 (b0.001) −0.14 (0.002) −0.11 (0.048) 16
WASF2 −0.18 (b0.001) −0.2 (0.002) −0.17 (0.040) 1
UBA52 −0.11 (b0.001) −0.12 (0.002) −0.1 (0.044) 19
NRGN −0.3 (b0.001) −0.33 (0.002) −0.26 (0.048) 11
AP1G2 −0.11 (b0.001) −0.11 (0.002) −0.1 (0.041) 14
KPNA6 −0.12 (0.001) −0.14 (0.002) −0.1 (0.057) 1
PBX2 −0.12 (b0.001) −0.13 (0.002) −0.11 (0.041) 6
Table of logFC andq-value of top upand down regulated probes for 3 comparisons (FEP vsHC, SCZ vsHC andOPvsHC) following differential expression analysis. Each comparison contains
the logFC value followed by theq-value in brackets. Geneswere included if the FDR adjusted q-valuewas less than 0.05 and the absolute log fold changewas above 0.1 in all 3 comparisons.
For a complete list of probes see supplementary table 2.
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expressed genes were identiﬁed (results not shown).
Differential expression analysis of Scz vs HC identiﬁed 1276differen-
tially expressed genes, while the OP vs HC differential expression re-
sulted in 284 signiﬁcant genes (see Supplementary Table 2). Gene
Enrichment identiﬁed 162 pathways in the Scz group, and 19 in the
OP group, 15 of which were present in both groups. The 4 pathways
unique to the OP group were related to NF-κB signalling, catabolic pro-
cesses and transcriptional regulation of gene expression (see Fig. 1, Sup-
plementary Table 3).
Differentially expressed genes were again correlated with PANSS
subscales, and pathway analysis was performed. In the Scz group we
identiﬁed 202 and 37 probes that were signiﬁcantly correlated with
positive and negative symptoms, respectively, while in the OP group
we found 5 and 9 probes respectively (Supplementary Table 4).
Pathway analysis of correlated probes was not performed for the OP
group due to the low number of probes. For the Scz group, pathway
analysis identiﬁed 11 pathways correlated with positive symptoms in-
cluding immune pathways (lymphocyte/leukocyte activation, cytokine
production), the cytosol, response to protein misfolding, exosome
transport and four brain related pathways (neuronal cytoplasm,
synaptome, glutamatergic synapse and post synaptic density). For neg-
ative symptoms the only pathway identiﬁed was related to RNA catab-
olism (Supplementary Table 4).
3.4. Anti-psychotic medication
In thedifferential expression comparison between the threemedica-
tion groups (Olanzapine, Risperidone, antipsychotic free [AF]) and con-
trols, we identiﬁed no signiﬁcant DE genes in the Risperidone - HC
comparison, but did ﬁnd 1132 and 338 DE genes in the Olanzapine -
HC and AF - HC comparisons respectively (see Supplementary
Table 5). To visualise the effect of medication, we used the 978 signiﬁ-
cant DE genes from the full FEP – HC comparison, and plotted the fold
change for these genes in the three medication subsets (see Fig. 2),
The direction (meaning up or down regulation) of differentialPlease cite this article as: D.J. Leirer, C.O. Iyegbe, M. Di Forti, et al., Differenti
Schizophrenia Research, https://doi.org/10.1016/j.schres.2019.05.011expression compared to healthy controls was generally preserved
across the three groups, but the magnitude (or fold change) of probes
tended to be greater for the antipsychotic free group than for the
olanzapine or risperidone groups, as can be seen in Fig. 2. In addition,
no differentially expressed genes were found when comparing either
of the antipsychotic groups with the antipsychotic free group.
4. Discussion
4.1. First episode psychosis patients show deregulation in immune
pathways
Our results suggest an immune deregulation component in psycho-
sis patients,which is in linewith expectations due to previous GAP stud-
ies (Mondelli et al., 2011, 2015; Di Nicola et al., 2013). Notably we ﬁnd
an upregulation of the antimicrobial α-defensins (DEFA1B, DEFA1 and
DEFA3), which was independently reported for schizophrenia in a tran-
scriptome study by Gardiner et al. (2013). Gene enrichment analysis re-
vealed dysregulation in multiple pathways that are related to oxidative
stress, NF-κB signalling and the Ribosome, which is consistent with the
results by Hess et al. (2016).
4.2. Patients meeting criteria for a diagnosis of schizophrenia have a more
pronounced blood signature
We identiﬁed 1276 differentially expressed genes in the Scz vs HC
comparison. This number was higher than what was found in similar
gene expression studies of chronic schizophrenia (Gardiner et al.,
2013), and may be explained by blood samples, in this study, being
taken soon after patients were admitted to hospital, since the samples
used in this study areﬁrst episode. As such the reported gene expression
signaturemaymore closely reﬂect the expression changes during acute
psychosis, rather than during remission, and they might be less con-
founded by the effects of long-term antipsychotic treatment.
Comparing the result from Scz and OP analyses, we ﬁnd more
than fourfold as many differentially expressed genes, and pathwaysal gene expression analysis in blood of ﬁrst episode psychosis patients,
Table 3
Enriched Gene Sets: FEP vs HC.
Gene set Library P-value # Genes
Kyoto Encyclopedia of Genes and Genomes
Ribosome KEGG b0.001 46 FAU, MRPL11, MRPL3, RPL17, RPL21, UBA52
Oxidative phosphorylation KEGG b0.001 28 ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRH
Parkinson's disease KEGG b0.001 27 ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRH
Alzheimer's disease KEGG b0.001 26 ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRH
Huntington's disease KEGG 0.001 26 ATP5C1, COX17, NDUFA1, PPA1, SDHD, UQCRH
Gene Ontology: Biological Process
Cytokine production GOBP 0.007 14 CASP1, CD46, G6PD, IL1B, PIK3CD, TBK1, TNFAIP8
T cell receptor GOBP 0.009 16 CARD11, CD3D, FYN, LAT, NCK1, RBCK1, UBE2N
Leukocyte activation GOBP 0.02 37 AIF1, ANXA1, CD3E, CD48, CD7, CD79A, CD93, CXCR4, FYN, FZD7, GAPT, ITGAL, LAT, LYL1, SP3, VAMP7
Regulation of NF-kB GOBP 0.041 25 BIRC2, CARD11, CASP1, CD36, CXXC5, FYN, HSPB1, IL1B, IRF3, RBCK1, UBE2N
Defense response to
Bacteria
GOBP 0.043 11 CAMP, CD36, DEFA1, FAU, HIST2H2BE, MYO1F, PGLYRP1, RPL39, TBK1, TNFAIP8
Gene Ontology: Cellular Component
Cytosol GOCC b0.001 238 ATG3, BCR, DCP2, FYN, GMIP, GNAS, IL1B, IRF3, LYST, NDE1, NME1, PARK7, TBK1, UBA1, USP7
Ribosomal subunit GOCC b0.001 45 FAU, FXR2, MRPL3, RPL11, RPS15A, RPS3, RPS9
Nucleolus GOCC b0.001 127 AATF, CD79B, HIF1A, ILF3, IP6K1, JUND, NIN, PCNA, PTEN, RNF7, RPL11, STAT3, ZFR
Mitochondrion GOCC 0.002 90 ATP5L, COQ5, COX7C, CYBB, ILF3, NME1, NUBPL, OAS2, PARK7, REXO2, TPP1, UCP2
Lysosome GOCC 0.01 29 CTNS, CTSA, CTSB, CTSZ, CXCR4, FUCA1, GALC, HEXB, LAT, SRGN, TPP1, USP4
Gene Ontology: Biological Process
Ribosome GOMF b0.001 45 FAU, MRPL11, RPL27, RPS3, RPS3A, RPSA
Ion transport GOMF b0.001 18 ATP5C1, ATP5E, COX6A1, NDUFA4, SLC9A1, UQCRH
Blood Module Library (WGCNA)
Red Blood Cell Blood b0.001 170 ADD3, BAT3, CD48, IL8RB, JUND, LAMP2, LDHA, LYST, MED1, PARK7, STAT3, TBK1, UBN1
Blood Platelets Blood b0.001 39 ACTN1, ANXA1, BCR, GNAS, GP9, JUND, LCN2, NRGN, TAGLN2, VCL
Brain Module Library (WGCNA)
Post Synaptic Density
Proteins
Brain b0.001 133 AGL, BAT3, BCR, FASN, FYN, G6PD, HGS, MSN, MTDH, MYH9, NME1, SEPT5, SND1, TAGLN2, TBK1, TLN1, TUBB2C, UBA1,
VAMP2
Pyramidal Neurons
(Amygdala)
Brain b0.001 37 ACSL4, CRBN, DDR1, ENY2, GMFB, HDAC2, MATR3, NME1, PCNA, TBK1, UBE3A
Down in Alzheimer's Brain b0.001 80 ACP1, ATP5O, ELMO1, GLO1, GMFB, GNAS, HEXB, ICA1, NME1, PARK7, STX7, TAF7, UBL3
Glutamatergic synapse Brain b0.001 49 ARF3, ATG3, BAT3, CABIN1, CENTB2, CPD, CTSD, DEK, GCA, GPR137, HGS, NRGN, PRNP, RARA, SPOCK2, SPTAN1, SRP9,
TBCA, TIA1, UBE1, VAMP2
CD40 stimulated Microglial
cells
Brain b0.001 58 ACP1, BCR, CARM1, DDR1, FYN, ILF3, IRF3, NME1, SLC9A1, TRIM28, UBE2L3, VAMP2
Table of select gene sets enrichedwith differentially expressed (n=978) genes between FEP andHC. P-values are Bonferroni corrected. Total number of DE genes present in each gene set
are indicated in the # column. List of gene sets and gene symbols is not exhaustive, for complete results see supplementary table 2.
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neity. Interestingly 215 of the 284 dysregulated genes in the OP
group, were also found in the Schizophrenia group. Furthermore,
the direction of change was the same in both groups, although the
log fold change in expression was lower for OP (see Table 2). ThisTable 4
Gene sets correlated with symptom severity.
Gene set Library P-value # Genes
PANSS Positive symptom correlated pathways
Measles KEGG 0.0034 8 CD3E, CD46, FYN, IFNGR1, IL1B, IL2RB,
Cytokine production GOBP 0.009 6 CASP1, CD46, EOMES, IL1B, PTGS2, TBK
Regulation of NF-kB
signalling
GOBP 0.0168 8 CASP1, CXXC5, FYN, IL1B, IRF3, PELI1,
Red Blood Cell Blood 0.0199 18 BAZ2B, CD46, CKLF, COX7A2, DYNLT1,
TNFAIP6, TXN
Ras signalling KEGG 0.0219 9 CSF1R, GNG10, LAT, RAB5A, RASAL3, R
Cytosol GOCC 0.035 31 ALDOC, CAPZA2, CASP1, DPYD, FASN, F
TXN, UBE2E1, USP7
PANSS Negative symptom correlated pathways
Viral transcription GOBP b0.001 8 RPL11, RPL21, RPL35, RPL4, RPL5, RPS3
Cytosolic part GOCC b0.001 9 AHR, RPL11, RPL21, RPL35, RPL4, RPL5
Ribosome GOMF b0.001 8 RPL11, RPL21, RPL35, RPL4, RPL5, RPS3
Ribosome KEGG b0.001 8 RPL11, RPL21, RPL35, RPL4, RPL5, RPS3
Mitochondria Brain 0.0071 6 COX6C, NDUFS5, PPA2, RPL11, RPL4, R
Table of gene sets enrichedwith DE genes signiﬁcantly correlated to positive or negative sympto
Negative symptomswere used for gene enrichment analysis. Signiﬁcant pathways are shown se
of DE genes overlapping with gene sets are indicated in the # column. For complete results, in
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diagnostic categories.
Interestingly 12 of the 19 signiﬁcant pathways in the OP group are
from brain speciﬁc pathway libraries, and all 12 were also identiﬁed in
the Scz group (Fig. 1, Supplementary Table 3). A recent study poolingIRF3, TBK1
1
PTGS2, TBK1
GALC, GNG10, IFNGR1, LYST, PELI1, PTGS2, RAB5A, RNF13, SHOC2, SRGN, TBK1,
ASGRP2, SHOC2, TBK1, ZAP70
YN, IDH1, IL1B, IRF3, ITPKB, LYST, MATK, OSBPL7, PDE7A, PELI1, PTEN, RAP2C, TBK1,
, RPS5, RPS6
, RPS3, RPS5, RPS6
, RPS5, RPS6
, RPS5, RPS6
PL5
ms in FEP. The 120 and37DEgenes signiﬁcantly correlated, respectively,with Positive and
parately for the two symptomdimensions. P-values are Bonferroni corrected. Total number
cluding genes correlated with symptom severity, see supplementary table 4.
al gene expression analysis in blood of ﬁrst episode psychosis patients,
Fig. 1. Summary of Enrichment results for Schizophrenia and Other Psychosis. Venn diagram summarising and comparing Gene Set Enrichment results between Schizophrenia (Scz) and
Other Psychoses (OP) groups. Differentially expressed genes from comparisonswith healthy controls (HC)were used. A total of 8 gene set librarieswith a combined 4479 categorieswere
used. The Bonferroni corrected p-value cut-off for gene sets was 0.05. Pathways and functions associatedwith signiﬁcant gene sets are highlighted in red (for pathways unique to a group)
and green (for pathways present in both groups). The FEP vs HC comparison is not included since the results are a combination of the Scz and OP results. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
7D.J. Leirer et al. / Schizophrenia Research xxx (xxxx) xxx18 schizophrenia transcriptome cohorts found that 50% of blood
enriched pathways were also enriched in brain tissue (Hess et al.,
2016). While we do not suggest that these results accurately reﬂect
gene expression patterns in the brains of patients, it is interesting to
note that the overlapping brain pathways include Alzheimer's Disease,
the Amygdala and Microglial markers. This might be consistent with a
neuro-inﬂammatory model of psychosis.
4.3. Positive symptom severity is correlated with immune function
Interestingly, we found that positive symptom severity was corre-
lated with immune pathways, both in the full FEP cohort, and in the
Scz subset. One explanation for these results is that psychosocial and en-
vironmental stressors, trigger innate immune pathways, for example
via the Hypothalamic pituitary adrenal (HPA) axis. This has been re-
ported in previous FEP studies (Di Nicola et al., 2013; Mondelli et al.,
2011) and our results for positive symptoms are consistent with an up-
regulation in NF-κB signalling, which can be modulated by the above-
mentioned stressors.
For the Scz subset we also found a correlation with multiple brain
expressed categories, including glutamatergic synapses. Interestingly
the glutamatergic signal was in part due to Neurogranin (NRGN),
which was found to be downregulated in all groups, and this downreg-
ulation was signiﬁcantly correlated with positive symptom severity in
the Scz subset. NRGN was one of the ﬁrst GWAS schizophrenia hits
(Stefansson et al., 2009), and has been shown to be downregulated in
brain tissue of schizophrenics (Broadbelt et al., 2006).
In contrast pathways correlated with Negative symptom severity
were less interpretable. This was partially because we only identiﬁed
38 probes that were signiﬁcantly correlated to negative symptoms,
while we identiﬁed 203 for positive symptoms (see Supplementary
Table 4). As a result, pathways for negative symptoms were almost ex-
clusively driven by 8 ribosomal genes (RPL11, RPL21, RPL35, RPL4, RPL5,
RPS3, RPS5, RPS6) (see Table 4). As such our results in themost generalPlease cite this article as: D.J. Leirer, C.O. Iyegbe, M. Di Forti, et al., Differenti
Schizophrenia Research, https://doi.org/10.1016/j.schres.2019.05.011terms suggest that negative symptom severity is correlated with
changes in translation.4.4. Anti-psychotic medication reduces magnitude of psychosis blood
signature
Our results suggest that the effect of antipsychotics reduces the de-
tectable blood signature associated with psychosis, without introducing
an overwhelmingly confounding gene expression signature speciﬁc to
anti-psychotics. This is consistent with previous ﬁndings by Crespo-
Facorro et al. (2015), where antipsychotics appeared to shift expression
levels towards what is seen in HC. This reduces the magnitude of a
medication-naive psychosis blood signature and introduces a confound-
ing in the overall signature by introducing medication speciﬁc changes.
It should be noted that 8 antipsychotic medications were used to stabi-
lise patients in this study, and these are likely to have different non-
speciﬁc effects on gene expression. This is expected to reduce the con-
founding effect speciﬁc to a single drug in the overall FEP - HC results.
Moreover, FEPwere recruited shortly after their ﬁrst contact with Men-
tal Health services and therefore were on average within the ﬁrst two
weeks of pharmacological treatment.4.5. Limitation
Amajor limitation of this study is that we were unable to control for
several important confounders such as BMI, smoking, drugs and medi-
cations other than antipsychotics. It is possible that these factors could
have a signiﬁcant impact on cell composition and gene expression in
whole blood.Whilewe did usemethods such as surrogate variable anal-
ysis to detect potential major unknown confounders, and CellMix to es-
timate variations in cell composition, it is ultimately not possible to
adjust for all possible sources of variation.al gene expression analysis in blood of ﬁrst episode psychosis patients,
Fig. 2. Gene Expression Change across Medication Groups. Heatmap comparing differential expression, between anti-psychotic medication groups and healthy controls. Anti-psychotic
free (AF, N = 18), Olanzapine (Ola, N = 46) and Risperidone (Ris, N = 27) patients were compared to healthy controls (HC, N = 149). Results were subset to signiﬁcant DE genes
from the full FEP vs HC comparison, and fold change was plotted. The direction of gene expression tends to be preserved in the three comparisons.
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Overall, we found evidence for multiple disrupted pathways in the
blood of ﬁrst episode psychosis patients, speciﬁcally in immune signal-
ling and transcription/translation. In addition, we found that positive
symptom severity correlated with genes involved in immune signalling
while negative symptom severity correlated with changes in transcrip-
tion. These signatures were more pronounced in individuals meeting
the criteria for a diagnosis of schizophrenia, but they were detectable
to some extent in other types of psychosis. These effects could not be at-
tributed to anti-psychoticmedication administered to stabilise patients,
since anti-psychotic free patients showed higher magnitude changes in
gene expression.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.schres.2019.05.011.Contributors
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